Electronic Resource
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i)
| العنوان: | Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i) |
|---|---|
| المؤلفون: | Gillessen, Sarah, Huettmann, Andreas, Vucinic, Vladan, Mueller, Horst, Pluetschow, Annette, Viardot, Andreas, Topp, Max S., Kobe, Carsten, Boell, Boris, Eichenauer, Dennis A., Sasse, Stephanie, Haverkamp, Heinz, Schmitz, Christine, Borchmann, Sven, Broeckelmann, Paul J., Heger, Jan-Michel, Fushs, Michael, Engert, Andreas, Borchmann, Peter, von Tresckow, Bastian |
| بيانات النشر: | WILEY 2022 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Reinduction chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant (HDCT + ASCT) is second-line standard of care for transplant-eligible patients with relapsed/refractory classical Hodgkin lymphoma (r/r cHL) but has a high failure rate. Because response to reinduction is predictive of the outcome after HDCT + ASCT, we aimed to improve the standard dexamethasone, high-dose cytarabine and cisplatinum (DHAP) reinduction regimen by addition of the oral mammalian target of rapamycin inhibitor everolimus (everDHAP). Transplant-eligible patients aged 18-60 years with histologically confirmed r/r cHL were included in this experimental phase I/II trial. Everolimus (10 mg/day, determined in phase-I-part) was administered on day 0-13 of each DHAP cycle. From July 2014 to March 2018, 50 patients were recruited to the phase II everDHAP group; two were not evaluable, three discontinued due to toxicity. Randomization to a placebo group stopped in October 2015 due to poor recruitment after nine patients. The primary end-point of computed tomography (CT)-based complete remission (CR) after two cycles of everDHAP was expected to be >= 40%. With a CT-based CR rate of 27% (n = 12/45) after two cycles of everDHAP the trial did not meet the primary end-point. Adding everolimus to DHAP is thus feasible; however, the everDHAP regimen failed to show an improved efficacy. |
| مصطلحات الفهرس: | ddc:no, doc-type:article, publishedVersion |
| URL: | 10.1111/bjh.17878 |
| الاتاحة: | Open access content. Open access content |
| ملاحظة: | English |
| Other Numbers: | K7U oai:USBKOELN.ub.uni-koeln.de:59446 Gillessen, Sarah, Huettmann, Andreas, Vucinic, Vladan, Mueller, Horst, Pluetschow, Annette, Viardot, Andreas, Topp, Max S., Kobe, Carsten, Boell, Boris, Eichenauer, Dennis A. ORCID: 0000-0002-1927-3514 <https://orcid.org/0000-0002-1927-3514>, Sasse, Stephanie, Haverkamp, Heinz, Schmitz, Christine, Borchmann, Sven, Broeckelmann, Paul J., Heger, Jan-Michel, Fushs, Michael, Engert, Andreas, Borchmann, Peter and von Tresckow, Bastian (2022). Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i). Br. J. Haematol., 196 (3). S. 606 - 617. HOBOKEN: WILEY. ISSN 1365-2141 1364968548 |
| المصدر المساهم: | UNIVERSITATS- UND STADTBIBLIOTHEK KOLN From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1364968548 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |